期刊
EUROPEAN HEART JOURNAL
卷 35, 期 7, 页码 470-473出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/eht555
关键词
Heart failure
资金
- Novartis
- Boehringer
- Bayer
- Pfizer
- Roche
Heart failure has become a worldwide epidemic of the 21st century with increasing impact on healthcare systems. The 2012 ESC and 2013 ACCF/AHA guidelines have set the stage for current therapy to reduce mortality and morbidity. There is a dawn of hope for therapy of acute and diastolic heart failure; it has become clearer that patients benefit from mitral reconstruction and which patients benefit from heart failure management programmes; genetics and proteomics advance in great strides; competing concepts of cell therapy seem to spiral, hopefully upwards; and we can further nurture our hope for evidence-based individualized diagnostic and therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据